METHOD FOR TREATING CANCER WITH A COMBINATION OF QUERCETIN AND A CHEMOTHERAPY AGENT
A method for treating cancer with a combination of a chemotherapy agent and a composition that includes quercetin. The composition can also include one or more of vitamin B3, vitamin C, and folic acid.
1 . A method for treating cancer, the method comprising administering to a subject in need thereof an effective amount of a combination of a chemotherapy agent and a composition containing a quercetin.
2 . The method of claim 1 , wherein the cancer is breast cancer, bladder cancer, kidney cancer, or colorectal cancer.
3 . The method of claim 1 , wherein the cancer is a metastatic cancer.
4 . The method of claim 1 , wherein the chemotherapy agent is a tyrosine kinase inhibitor.
5 . The method of claim 4 , wherein the tyrosine kinase inhibitor is everolimus, axitinib, sorafenib tosylate, pazopanib hydrochloride, sunitinib, temsirolimus, erlotinib, or regorafenib.
6 . The method of claim 2 , wherein the cancer is colorectal cancer and the chemotherapy agent is fluorouracil, bevacizumab, irinotecan hydrochloride, capecitabine, cetuximab, oxaliplatin, leucovorin calcium, panitumumab, regorafenib, or ziv-aflibercept.
7 . The method of claim 2 , wherein the cancer is bladder cancer and the chemotherapy agent is cyclophosphamide, doxorubicin hydrochloride, cisplatin, gemcitabine, or a combination of gemcitabine and cisplatin.
8 . The method of claim 7 , wherein the bladder cancer is metastatic and the chemotherapy agent is cyclophosphamide.
9 . The method of claim 8 , wherein the cyclophosphamide is administered at a daily dose of 0.3 mg/kg to 2.5 mg/kg together with 2 g of a quercetin.
10 . The method of claim 9 , wherein the quercetin is in the form of isoquercetin or isoquercitrin.
11 . The method of claim 7 , wherein the bladder cancer is metastatic and the chemotherapy agent is doxorubicin.
12 . The method of claim 2 , wherein the cancer is kidney cancer and the chemotherapy agent is cyclophosphamide, everolimus, aldesleukin, bevacizumab, axitinib, sorafenib tosylate, pazopanib hydrochloride, sunitinib, or temsirolimus.
13 . The method of claim 12 , wherein the kidney cancer is metastatic and the chemotherapy agent is sunitinib.
14 . The method of claim 13 , wherein the effective amount is an amount that provides 5 mg to 25 mg sunitinib and 250 mg to 5 g of a quercetin per day.
15 . The method of claim 1 , wherein the quercetin is selected from the group consisting of quercetin aglycone, isoquercetin, and isoquercitrin.
16 . The method of claim 15 , wherein the composition further includes vitamin B 3 , vitamin C, folic acid, or a combination thereof.
17 . An in vitro method for identifying a target for a chemotherapy agent, the method comprising:
culturing a cancer cell line,
contacting the cultured cancer cell line with a chemotherapy agent known to be ineffective for inhibiting growth of the cancer cell line and a composition containing quercetin,
further culturing the contacted cultured cell line, and
measuring the growth of the cancer cell line,
wherein an inhibition of growth of the cancer cell line indicates that a cancer from which the cancer cell line was derived is a target for the chemotherapy agent.
18 . The method of claim 17 , wherein the composition further contains vitamin B3, vitamin C, folic acid, or a combination thereof.
19 . An in vitro screening method for determining an effective chemotherapy agent for a cancer patient, the method comprising:
isolating tumor cells from a patient,
culturing the tumor cells in vitro,
contacting the cultured tumor cells with a panel of chemotherapy agents and a composition containing quercetin,
further culturing the contacted cultured tumor cells, and
measuring the growth of the tumor cells,
wherein an inhibition of growth of the tumor cells indicates that the chemotherapy agent is an effective chemotherapy agent for the cancer patient.
20 . The method of claim 19 , wherein the composition further contains vitamin B3, vitamin C, folic acid, or a combination thereof.